BEYOND THE ADJUVANT: PROVING THE HUMAN IMMUNE RESPONSE
The future of vaccine adjuvants is not just what they contain, but what they make human immunity do.

Two vaccine adjuvants can meet similar specifications yet generate different immune responses. That distinction matters.

Composition, purity and stability tell only part of the story. The critical question is how an antigen–adjuvant formulation performs within human immune biology.

Transcell Biologics’ DART (Digital Animal Replacement Technology) integrates a Human MicroPhysiological Platform with AI-powered analysis to study immune activation, T-cell proliferation, cytokine profiles and antibody-associated responses.

Its exploratory assessments distinguished biological response patterns across experimental conditions, supporting more informed formulation screening.

For adjuvant manufacturers, human functional evidence creates an opportunity to move beyond specification-led competition toward scientific differentiation. For vaccine developers, it offers earlier insights into candidate selection, immune-response quality and potential tolerability signals.

DART-generated data can complement established nonclinical analytical and regulatory evidence for specific uses.

The next frontier in vaccine adjuvants is not just what they contain. It is what they make human immunity do